Patents Assigned to Prochon Biotech Ltd.
-
Publication number: 20180127475Abstract: The present invention relates to the design, manufacture and use of fibroblast growth factor (FGF) polypeptides having improved receptor specificity. In particular, the invention relates to isolated FGF2 and FGF4 polypeptides comprising a truncated N-terminus and optionally N-terminal amino acid substitutions. The present invention provides polypeptides, nucleic acids encoding the polypeptides, compositions comprising same and methods for use thereof.Type: ApplicationFiled: December 12, 2017Publication date: May 10, 2018Applicants: PROCHON BIOTECH LTD., HEPACORE LTD.Inventors: Avner Yayon, Eran Rom, Irina Chumakov, Sara Blumenstein
-
Patent number: 9862753Abstract: The present invention relates to the design, manufacture and use of fibroblast growth factor (FGF) polypeptides having improved receptor specificity. In particular, the invention relates to isolated FGF2 polypeptides comprising a truncated N-terminus and optionally N-terminal amino acid substitutions. The present invention provides polypeptides, nucleic acids encoding the polypeptides, compositions comprising same and methods for use thereof.Type: GrantFiled: February 23, 2015Date of Patent: January 9, 2018Assignees: PROCHON BIOTECH LTD., HEPACORE LTDInventors: Avner Yayon, Eran Rom, Irina Chumakov, Sara Blumenstein
-
Patent number: 9487568Abstract: A method of treating an individual (i) having abnormal bone; or (ii) afflicted with a disease or disorder related to normal or abnormal FGF receptors or a skeletal disorder; or (iii) having dysplasic bone. The method includes administering to the individual a pharmaceutical composition comprising a therapeutically effective amount of a fibroblast growth factor 9 (FGF-9) variant comprising at least one amino acid substitution in the beta 8-beta 9 loop, wherein said FGF-9 variant incorporates one of the amino acid sequences set forth in SEQ ID NO: 11, 13, 14, 15, 16 or 17.Type: GrantFiled: November 19, 2014Date of Patent: November 8, 2016Assignee: PROCHON BIOTECH LTD.Inventors: Oren Bogin, Avner Yayon
-
Patent number: 8962556Abstract: The present invention relates to the design, manufacture and use of fibroblast growth factor (FGF) polypeptides having improved receptor specificity. In particular, the invention relates to isolated FGF2 and FGF4 polypeptides that include a truncated N-terminus and optionally N-terminal amino acid substitutions. The present invention provides polypeptides, nucleic acids encoding the polypeptides, compositions of the same and methods for use thereof.Type: GrantFiled: October 7, 2007Date of Patent: February 24, 2015Assignee: Prochon Biotech Ltd.Inventors: Avner Yayon, Eran Rom, Irina Chumakov, Sara Blumenstein
-
Patent number: 8940888Abstract: Disclosed are chemically modified hyaluronic acid (HA) derivatives containing hydrazido groups directly linked to the glucuronic acid residues of HA. Said hydrazido groups are used to obtain crosslinked and labeled HA derivatives. The invention further relates to methods of preparation of said HA derivatives.Type: GrantFiled: August 29, 2013Date of Patent: January 27, 2015Assignee: Prochon Biotech Ltd.Inventors: Boaz Amit, Avraham Wortzel, Avner Yayon
-
Patent number: 8916522Abstract: A method of treating an individual (i) having abnormal bone; or (ii) afflicted with a disease or disorder related to normal or abnormal FGF receptors or a skeletal disorder; or (iii) having dysplasic bone. The method includes administering to the individual a pharmaceutical composition comprising a therapeutically effective amount of a fibroblast growth factor 9 (FGF-9) variant comprising at least one amino acid substitution in the beta 8-beta 9 loop, wherein the FGF-9 variant incorporates one of the amino acid sequences set forth in SEQ ID NO: 11, 13, 14, 15, 16 or 17.Type: GrantFiled: July 30, 2013Date of Patent: December 23, 2014Assignee: ProChon Biotech Ltd.Inventors: Oren Bogin, Avner Yayon
-
Publication number: 20140005141Abstract: Disclosed are chemically modified hyaluronic acid (HA) derivatives containing hydrazido groups directly linked to the glucuronic acid residues of HA. Said hydrazido groups are used to obtain crosslinked and labeled HA derivatives. The invention further relates to methods of preparation of said HA derivatives.Type: ApplicationFiled: August 29, 2013Publication date: January 2, 2014Applicants: Bio-Technology General (Israel) Ltd., Prochon Biotech Ltd.Inventors: Boaz AMIT, Avraham Wortzel, Avner YAYON
-
Patent number: 8618258Abstract: Methods for treating diseased or injured tissue by implanting into the tissue at a site of the disease or injury a porous freeze-dried fibrin matrix formed from plasma proteins. The proteins include fibrinogen cleaved by the action of thrombin at varying concentrations sufficient to cleave the fibrinogen and Factor XIII. The matrix has less than 10% residual moisture and is devoid of exogenous anti-fibrinolytic agents, plasminogen and of organic chelating agents. Alternatively, the plasma proteins comprise partially purified plasma proteins that are devoid of plasminogen.Type: GrantFiled: May 7, 2012Date of Patent: December 31, 2013Assignee: Prochon Biotech Ltd.Inventors: Avner Yayon, Malkit Azachi, Micha Gladnikoff
-
Publication number: 20130338070Abstract: A method of treating an individual (i) having abnormal bone; or (ii) afflicted with a disease or disorder related to normal or abnormal FGF receptors or a skeletal disorder; or (iii) having dysplasic bone. The method includes administering to the individual a pharmaceutical composition comprising a therapeutically effective amount of a fibroblast growth factor 9 (FGF-9) variant comprising at least one amino acid substitution in the beta 8-beta 9 loop, wherein said FGF-9 variant incorporates one of the amino acid sequences set forth in SEQ ID NO: 11, 13, 14, 15, 16 or 17.Type: ApplicationFiled: July 30, 2013Publication date: December 19, 2013Applicant: ProChon Biotech, Ltd.Inventors: Oren BOGIN, Avner YAYON
-
Patent number: 8609823Abstract: The present invention provides fibroblast growth factor variants demonstrating enhanced receptor subtype specificity and/or affinity. Preferred embodiments include both variants having enhanced activity that act as improved agonists and variants having reduced activity that act as antagonists. Methods of utilizing preferred FGF variants in preparation of medicaments for the treatment of skeletal disorders including skeletal dysplasia, osteoporosis and enhancing bone fracture healing and cartilage healing processes are provided.Type: GrantFiled: January 11, 2012Date of Patent: December 17, 2013Assignee: ProChon Biotech, Ltd.Inventors: Oren Bogin, Avner Yayon
-
Patent number: 8524885Abstract: Disclosed are chemically modified hyaluronic acid (HA) derivatives containing hydrazido groups directly linked to the glucuronic acid residues of HA. Said hydrazido groups are used to obtain crosslinked and labeled HA derivatives. The invention further relates to methods of preparation of said HA derivatives.Type: GrantFiled: March 6, 2007Date of Patent: September 3, 2013Assignees: Prochon Biotech Ltd., Bio-Technology General (Israel) Ltd.Inventors: Boaz Amit, Avraham Wortzel, Avner Yayon
-
Publication number: 20120219534Abstract: Methods for treating diseased or injured tissue by implanting into the tissue at a site of the disease or injury a porous freeze-dried fibrin matrix formed from plasma proteins. The proteins include fibrinogen cleaved by the action of thrombin at varying concentrations sufficient to cleave the fibrinogen and Factor XIII. The matrix has less than 10% residual moisture and is devoid of exogenous anti-fibrinolytic agents, plasminogen and of organic chelating agents. Alternatively, the plasma proteins comprise partially purified plasma proteins that are devoid of plasminogen.Type: ApplicationFiled: May 7, 2012Publication date: August 30, 2012Applicant: PROCHON BIOTECH LTD.Inventors: Avner Yayon, Malkit Azachi, Micha Gladnikoff
-
Publication number: 20120214739Abstract: The present invention provides fibroblast growth factor variants demonstrating enhanced receptor subtype specificity and/or affinity. Preferred embodiments include both variants having enhanced activity that act as improved agonists and variants having reduced activity that act as antagonists. Methods of utilizing preferred FGF variants in preparation of medicaments for the treatment of skeletal disorders including skeletal dysplasia, osteoporosis and enhancing bone fracture healing and cartilage healing processes are provided.Type: ApplicationFiled: January 11, 2012Publication date: August 23, 2012Applicant: PROCHON BIOTECH, LTD.Inventors: Oren Bogin, Avner Yayon
-
Patent number: 8193317Abstract: Methods for producing porous freeze-dried fibrin matrices substantially devoid of external anti-fibrinolytic agents. Resilient matrices, also known as sponges, that are particularly beneficial for supporting three dimensional cell growth are obtained from plasma proteins substantially devoid of plasminogen or from partially purified plasma proteins, thus obviating the need for exogenous anti-fibrinolytic agents. Furthermore, incorporation of glycosaminoglycans and bioactive agents during the formation of the matrix results in a sponge having advantageous biological, mechanical and physical properties. The compositions made by the method of the present invention are useful clinically or as cell-bearing implants.Type: GrantFiled: March 25, 2010Date of Patent: June 5, 2012Assignee: ProChon Biotech Ltd.Inventors: Avner Yayon, Malkit Azachi, Micha Gladnikoff
-
Patent number: 8119783Abstract: The present invention provides fibroblast growth factor variants demonstrating enhanced receptor subtype specificity and/or affinity. Preferred embodiments include both variants having enhanced activity that act as improved agonists and variants having reduced activity that act as antagonists. Methods of utilizing preferred FGF variants in preparation of medicaments for the treatment of skeletal disorders including skeletal dysplasia, osteoporosis and enhancing bone fracture healing and cartilage healing processes are provided.Type: GrantFiled: April 1, 2009Date of Patent: February 21, 2012Assignee: ProChon Biotech Ltd.Inventors: Oren Bogin, Avner Yayon
-
Patent number: 7714107Abstract: The present invention relates to porous freeze-dried fibrin matrices substantially devoid of external anti-fibrinolytic agents, and methods of producing such matrices. Resilient matrices, also known as sponges, that are particularly beneficial for supporting three dimensional cell growth are obtained from plasma proteins substantially devoid of plasminogen or from partially purified plasma proteins, thus obviating the need for exogenous anti-fibrinolytic agents. Furthermore, incorporation of glycosaminoglycans and bioactive agents during the formation of the matrix results in a sponge having advantageous biological, mechanical and physical properties. The compositions of the present invention are useful clinically, without cells or as a cell bearing implants.Type: GrantFiled: July 26, 2005Date of Patent: May 11, 2010Assignee: ProChon Biotech Ltd.Inventors: Avner Yayon, Malkit Azachi, Micha Gladnikoff
-
Patent number: 7563769Abstract: The present invention provides fibroblast growth factor variants demonstrating enhanced receptor subtype specificity and/or affinity. Preferred embodiments include both variants having enhanced activity that act as improved agonists and variants having reduced activity that act as antagonists. Methods of utilizing preferred FGF variants in preparation of medicaments for the treatment of skeletal disorders including skeletal dysplasia, osteoporosis and enhancing bone fracture healing and cartilage healing processes are provided.Type: GrantFiled: November 5, 2004Date of Patent: July 21, 2009Assignee: ProChon Biotech, Ltd.Inventors: Oren Bogin, Avner Yayon
-
Publication number: 20090149419Abstract: Disclosed are chemically modified hyaluronic acid (HA) derivatives containing hydrazido groups directly linked to the glucuronic acid residues of HA. Said hydrazido groups are used to obtain crosslinked and labeled HA derivatives. The invention further relates to methods of preparation of said HA derivatives.Type: ApplicationFiled: March 6, 2007Publication date: June 11, 2009Applicants: PROCHON BIOTECH LTD., Bio-Technology General (Israel) Ltd.Inventors: Boaz Amit, Avraham Wortzel, Avner Yayon
-
Publication number: 20080194682Abstract: The present invention discloses pharmaceutical compositions for the treatment of skeletal dysplasias, comprising as an active ingredient at least one natriuretic peptide. Unexpectedly, it has been shown that the natriuretic factors may be effective for bone elongation in situations of abnormal bone growth especially for achondroplasia. The effects of the natriuretic peptide may be further enhanced by prolonging its residence time or action at the target site.Type: ApplicationFiled: August 17, 2007Publication date: August 14, 2008Applicant: ProChon Biotech Ltd.Inventors: Myriam Golembo, Avner Yayon
-
Patent number: 7335508Abstract: The present invention relates to porous freeze-dried plasma protein matrices having an open channel structure and a concentration gradient of plasma proteins crosslinked by the action of thrombin, and methods of producing said matrices. The compositions of the present invention are useful clinically, per se or as cell-bearing implants.Type: GrantFiled: July 22, 2004Date of Patent: February 26, 2008Assignee: ProChon Biotech Ltd.Inventors: Avner Yayon, Hilla Barkay, Malkit Azachi